Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Laura A Genovesi, Amanda Millar, Elissa Tolson, Matthew Singleton, Emily Hassall, Marija Kojic, Caterina Brighi, Emily Girard, Clara Andradas, Mani Kuchibhotla, Dharmesh D Bhuva, Raelene Endersby, Nicholas G Gottardo, Anne Bernard, Christelle Adolphe, James M Olson, Michael D Taylor, Melissa J Davis, Brandon J Wainwright
GENOME MEDICINE | BMC | Published : 2021
BACKGROUND: Medulloblastoma (MB) is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side effects. METHODS: We identified candidate drugs for MB using a network-based systems-pharmacogenomics approach: based on results from a functional genomics screen, we identified a network of interactions implicated in human MB growth regulation. We then integrated drugs and their kno..View full abstract
Awarded by NIH/NCI
This work is supported by NIH/NCI RO1 CA112250, NIH/NCI RO1 CA135491 and Seattle Children's Brain Tumour Endowment (E.G and J.M.O), as well as the Kids Cancer Project (B.J.W), Brainchild (B.J.W), Children's Hospital Foundation (L.A.G and B.J.W), The Pirate Ship Foundation (R.E. and N.G.), Cure Brain Cancer Foundation (L.A.G and B.J.W) and Cure Brain Cancer Foundation National Breast Cancer Foundation (M.J.D).